Penumbra Inc Stock News

ALAMEDA, Calif. , May 23, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the William Blair Growth Stock Conference on Thursday, Jun

Investors interested in Medical - Instruments stocks are likely familiar with Globus Medical (GMED) and Penumbra (PEN). But which of these two stocks presents investors with the better value opportuni

Penumbra's (PEN) Thrombectomy product category shows encouraging growth trends, reflecting strong momentum in CAVT products.

Penumbra, Inc. (NYSE:PEN ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - Presid

ALAMEDA, Calif. , May 7, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended Marc

Several top-rated Zacks Medical sector stocks are standing out ahead of their quarterly reports on Tuesday, May 7.

ALAMEDA, Calif. , May 1, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the RBC Capital Markets Global Healthcare Conference on Wed

Penumbra's (PEN) latest offering is likely to enable physicians to restore blood flow more quickly and further minimize blood loss.

Investors with an interest in Medical - Instruments stocks have likely encountered both Globus Medical (GMED) and Penumbra (PEN). But which of these two companies is the best option for those looking

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Lightning Flash™ 2.0 features advanced computer assisted vacuum thrombectomy (CAVT) software, designed for increased efficiency and sensitivity to enhance removal of venous thrombus and treatment o

ALAMEDA, Calif. , April 9, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2024 after market clos

Investors are optimistic about Penumbra (PEN) on strength exhibited in the Thrombectomy business and global expansion.

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Penumbra (PEN) expects to materially increase both revenues and profitability in the company's international business in the next three years and beyond.